- EU Transdermal Patch: Generic Submission HallaGulla 2023-03-08 08:58
- Documentation of SS for LAI Achievwin 2023-02-06 13:40
- Documentation of SS for LAI dshah 2023-02-28 16:50
- Study Design: Two treatment or Four treatment NK 2023-01-23 09:38
- Study Design: Two treatment or Four treatment dshah 2023-01-23 10:43
- Study Design: Two treatment or Four treatment NK 2023-01-24 03:37
- Study Design: Two treatment or Four treatment ElMaestro 2023-01-23 15:05
- Study Design: Two treatment or Four treatment Relaxation 2023-01-23 16:10
- Study Design: Two treatment or Four treatment dshah 2023-01-23 10:43
- Initial dose and design issues abridged submission daily ER vs BID IR alejandro_jo1990 2022-09-15 15:35
- Bioequivalence of mirabegron 50 mg extended release Tablet Ibrahim Komeil 2021-02-20 11:36
- Replicate designs based on information of 2×2×2 design Helmut 2021-02-20 14:50
- Replicate designs based on information of 2×2×2 design Ibrahim Komeil 2021-02-20 18:34
- Assumption of authority? Helmut 2021-02-20 20:50
- Replicate designs based on information of 2×2×2 design Ibrahim Komeil 2021-02-20 18:34
- Bioequivalence of mirabegron 50 mg extended release Tablet jishnu 2022-08-04 09:09
- Bioequivalence of mirabegron 50 mg extended release Tablet qualityassurance 2022-08-04 15:47
- Replicate designs based on information of 2×2×2 design Helmut 2021-02-20 14:50
- Could we design the RCT as a non-inferiority trial at this situation? dennis001 2022-07-24 17:39
- Non-Superiority Helmut 2022-07-25 16:37
- Non-Superiority dennis001 2022-07-26 02:32
- Non-Superiority Helmut 2022-07-26 15:04
- Non-Superiority dennis001 2022-07-27 05:18
- Placebo effect Helmut 2022-07-27 12:17
- Non-Superiority dennis001 2022-07-27 05:18
- Non-Superiority Helmut 2022-07-26 15:04
- Non-Superiority dennis001 2022-07-26 02:32
- Could we design the RCT as a non-inferiority trial at this situation? ElMaestro 2022-07-26 12:44
- Could we design the RCT as a non-inferiority trial at this situation? dennis001 2022-07-27 05:21
- Non-Superiority Helmut 2022-07-25 16:37
- Drug-drug interaction with two different route of administration Mr.Rao 2022-07-13 13:51
- Drug-drug interaction with two different route of administration Mr.Rao 2022-07-14 09:05
- Drug-drug interaction with two different route of administration dshah 2022-07-20 10:27
- Drug-drug interaction with two different route of administration Mr.Rao 2022-07-21 11:24
- Drug-drug interaction with two different route of administration dshah 2022-07-21 18:51
- Drug-drug interaction with two different route of administration Mr.Rao 2022-07-22 07:23
- Drug-drug interaction with two different route of administration Mr.Rao 2022-07-27 08:31
- Interpreting results of a DDI study Helmut 2022-07-27 09:52
- Drug-drug interaction with two different route of administration Mr.Rao 2022-07-27 08:31
- Drug-drug interaction with two different route of administration Mr.Rao 2022-07-22 07:23
- Drug-drug interaction with two different route of administration dshah 2022-07-21 18:51
- Drug-drug interaction with two different route of administration Mr.Rao 2022-07-21 11:24
- Drug-drug interaction with two different route of administration dshah 2022-07-20 10:27
- Drug-drug interaction with two different route of administration Mr.Rao 2022-07-14 09:05
- ‘Two-at-a-Time’ approach with >3 treatments Helmut 2022-06-12 11:37
- ‘Two-at-a-Time’ approach with >3 treatments Shuanghe 2022-06-12 19:02
- ‘Two-at-a-Time’ approach with >3 treatments Helmut 2022-06-12 20:10
- ‘Two-at-a-Time’ approach with >3 treatments Shuanghe 2022-07-10 00:05
- ‘Two-at-a-Time’ approach; ≥3 treatments: new 🇷 script Helmut 2022-07-10 16:02
- ‘Two-at-a-Time’ approach; ≥3 treatments: new 🇷 script Shuanghe 2022-07-13 15:35
- You’re a NE🇷D! Helmut 2022-07-13 16:46
- ‘Two-at-a-Time’ approach; ≥3 treatments: new 🇷 script Shuanghe 2022-07-13 15:35
- ‘Two-at-a-Time’ approach; ≥3 treatments: new 🇷 script Helmut 2022-07-10 16:02
- ‘Two-at-a-Time’ approach with >3 treatments Shuanghe 2022-07-10 00:05
- ‘Two-at-a-Time’ approach with >3 treatments Helmut 2022-06-12 20:10
- ‘Two-at-a-Time’ approach with >3 treatments Shuanghe 2022-06-12 19:02
- BE study Design for Rivaroxaban 20 mg Tricky TAB 2022-07-04 11:33
- Rivaroxaban: FDA and others Helmut 2022-07-04 13:19
- Rivaroxaban: FDA and others Tricky TAB 2022-07-05 06:42
- Rivaroxaban: FDA and others Helmut 2022-07-05 09:49
- Rivaroxaban: FDA and others Tricky TAB 2022-07-06 06:52
- Rivaroxaban: FDA and others Helmut 2022-07-05 09:49
- Rivaroxaban: FDA and others Tricky TAB 2022-07-05 06:42
- Rivaroxaban: FDA and others Helmut 2022-07-04 13:19
- PK time points Vaibhav 2022-06-23 21:31
- PK time points dshah 2022-06-24 11:29
- Hydrocortisone BE studies for UK HallaGulla 2022-05-16 17:37
- Coefficient variation intra subject variability of librax Bebac user 2022-02-17 19:31
- Coefficient variation intra subject variability of librax khageswara Rao 2022-02-28 07:54
- Coefficient variation intra subject variability of librax Bebac user 2022-03-05 12:56
- Coefficient variation intra subject variability of librax khageswara Rao 2022-02-28 07:54
- With food administration SerhiiP 2022-01-20 09:20
- With food administration dshah 2022-01-20 11:49
- ODT in BE study Farmacevt 2022-01-18 16:01
- ODT in BE study dshah 2022-01-18 19:08
- Biosimilars M.Vasu 2011-11-24 14:01
- Biosimilars Helmut 2011-11-24 14:44
- Biosimilars M.Vasu 2011-11-28 12:33
- Healthy subjects vs. patients Helmut 2011-11-28 12:56
- Biosimilars drgunasakaran1 2012-02-06 13:57
- Biosimilars Ben 2011-12-16 19:04
- Biosimilars M.Vasu 2011-11-28 12:33
- Biosimilars Chiku 2012-02-03 06:43
- Biosimilars drgunasakaran1 2012-02-10 11:33
- Biosimilars Chiku 2012-02-10 12:03
- Biosimilars Kumarnaidu2 2021-10-22 07:53
- Biosimilars Chiku 2012-02-10 12:03
- Biosimilars drgunasakaran1 2012-02-10 11:33
- Biosimilars Helmut 2011-11-24 14:44